Nath Bio-Genes

- Cotton sales expected to grow 15%-20% annually. - Paddy sales projected to increase 10%-15%. - Vegetable segment anticipated to grow 20%-25%. - Plant nutrient supplements forecasted to expand rapidly with 25%-30% growth, contributing about 10% of current revenue and targeted to grow to 30%. - Diversified product portfolio including maize, bajra, mustard, cotton, paddy, vegetables, and supplements supports balanced growth. - Overall company growth targeted conservatively at 15%+, with potential upside if crop segments perform well. - Uzbekistan JV expected to scale seed production post initial trial success, potentially doubling production by next year. - Philippines export market viewed as supplementary "cherry on the cake," with uncertain but potential upside. - Revenue goal of crossing 500 crores targeted within 2-3 years, indicating steady top-line expansion driven by current and new products.

- The company targets a consistent sales growth of around 15% plus annually, with optimism for even 20-25% in some segments like vegetables and supplements. - Cotton expected to grow 15-20%, paddy 10-15%, vegetables 20-25%, supplements 25-30%, contributing to overall growth. - Gross profit margin maintained around 51-53%, with focus on product mix to sustain margins despite volume fluctuations. - PAT growth expected in the range of 15-20%, supported by both existing and new product portfolios, including potential growth from Uzbekistan and Philippines markets. - Management is conservative, expecting 15%+ growth but open to higher if achieved. - EBITDA for H1 FY25 was ₹42.18 crores, profit after tax was ₹36.78 crores, reflecting steady profitability. - No significant CAPEX planned; focus on optimizing working capital and leveraging vendor processing keeps costs controlled, supporting margins and profits. - Expansion and diversification across crops and supplements expected to drive steady operating earnings growth.

- Nath Bio-Genes does not maintain a traditional advance order book like manufacturing industries. - Instead, the company operates on an advanced booking basis through advance sales. - Last year, advance bookings amounted to approximately ₹70-80 crores for the next year. - There is no concept of formal advance orders as seed sales depend on seasonal demand and advance bookings. - The company emphasizes working capital funded by advance bookings and bank facilities without increasing bank debt for about three years. - No specific pending or current orderbook figures are mentioned.

- No current plans for CAPEX expenditure on plant and machinery, implying no immediate major funding needs (Page 20). - The company has maintained nearly zero long-term debt for about 5-7 years and pays interest only on working capital (Pages 15, 17). - Working capital is well managed and funded through advance bookings and bankers without raising new bank debt for nearly three years (Page 17). - No term loans exist currently; any short-term funds are raised via short-duration NCDs and customer deposits (Page 15). - No mention of any ongoing or planned equity fundraising during the call. - The focus appears on organic growth and operational stability with no talk of inorganic growth or fundraising until crossing a revenue threshold of 500 crores (Page 9). - Overall, no plans for new fundraising through debt or equity were indicated in the discussion.

- No CAPEX (capital expenditure) on plant and machinery is planned for this year or next year. - The company relies on vendors for processing rather than investing in own plant and machinery, leading to low CAPEX, saving on depreciation, maintenance, and breakage costs. - Over the past 5-7 years, there has been hardly any CAPEX recorded in the balance sheets. - Strategic growth plans focus on organic growth with continued emphasis on diversifying portfolios (cotton, paddy, vegetables, plant nutrient supplements). - The company is exploring opportunities in Uzbekistan with ongoing investment (about US$7-8 lakh so far) and hopes to scale based on performance by early next year. - Expansion in exports, such as in the Philippines, is considered a potential growth avenue but not a core dependency. - No inorganic growth via JV currently; consideration may come after crossing ₹500 crore revenue mark.